SCHEMBL17190844

SCHEMBL17190844

C(=N/Nc1ccc2ccccc2n1)\c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.78
SMN1; SMN2 Q16637 11/20 0.78
MAPT P10636 11/20 0.78
NPC1 O15118 11/20 0.78
RAB9A P51151 11/20 0.78
MEN1 O00255 9/20 0.78
KDM4E B2RXH2 8/20 0.78
GAA P10253 6/20 0.72
HTT P42858 5/20 0.72
NPSR1 Q6W5P4 2/20 0.72
LMNA P02545 2/20 0.72
POLB P06746 1/20 0.72
XBP1 P17861 1/20 0.72
TP53 P04637 2/20 0.64
PAX8 Q06710 1/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
ALDH1A1 P00352 4/20 0.63
MAPK1 P28482 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29033679 1.00 KMT2A (0.78) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL10143964 0.88 RAB9A (1.00) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4929465 0.83 PAX8 (0.73) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL1164645 0.78 PAX8 (1.00) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4405365 0.78 KMT2A (0.70) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL1164644 0.78 PAX8 (1.00) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL29692738 0.78 PAX8 (1.00) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL8043731 0.78 SMN1; SMN2 (0.57) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL8043733 0.78 SMN1; SMN2 (0.57) KMT2ASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL10144051 0.77 MAPT (1.00) KMT2ASMN1; SMN2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809550-B2 Quinolyl hydrazones for the treatment of tuberculosis and related diseases TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) 2017-11-07 US disclosed
US-9809550-B2 Quinolyl hydrazones for the treatment of tuberculosis and related diseases TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) 2017-11-07 US disclosed
US-20150299128-A1 QUINOLYL HYDRAZONES FOR THE TREATMENT OF TUBERCULOSIS AND RELATED DISEASES TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299128-A1 QUINOLYL HYDRAZONES FOR THE TREATMENT OF TUBERCULOSIS AND RELATED DISEASES PGLS, CYP51A1, LCT KMT2A 2993/4885SMN1; SMN2 4342/4885MAPT 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.